New hope for rare lymphoma: drug combo targets tough cancer
NCT ID NCT06925555
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding brentuximab vedotin to standard chemotherapy (R-CHP) works better for people newly diagnosed with a rare, aggressive lymphoma linked to the Epstein-Barr virus. About 25 adults will receive the combination and be followed for 2 years to see if the cancer stays away. The goal is to improve disease control, not to cure the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRENTUXIMAB VEDOTIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.